Market Research Logo

Porphyria (Erythropoietic Protoporphyri) - Pipeline Review, H1 2016

Porphyria (Erythropoietic Protoporphyri) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Porphyria (Erythropoietic Protoporphyri) - Pipeline Review, H1 2016’, provides an overview of the Porphyria (Erythropoietic Protoporphyri) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Porphyria (Erythropoietic Protoporphyri), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Porphyria (Erythropoietic Protoporphyri) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Porphyria (Erythropoietic Protoporphyri)
  • The report reviews pipeline therapeutics for Porphyria (Erythropoietic Protoporphyri) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Porphyria (Erythropoietic Protoporphyri) therapeutics and enlists all their major and minor projects
  • The report assesses Porphyria (Erythropoietic Protoporphyri) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Porphyria (Erythropoietic Protoporphyri)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Porphyria (Erythropoietic Protoporphyri)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Porphyria (Erythropoietic Protoporphyri) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Porphyria (Erythropoietic Protoporphyri) Overview
Therapeutics Development
Pipeline Products for Porphyria (Erythropoietic Protoporphyri) - Overview
Pipeline Products for Porphyria (Erythropoietic Protoporphyri) - Comparative Analysis
Porphyria (Erythropoietic Protoporphyri) - Therapeutics under Development by Companies
Porphyria (Erythropoietic Protoporphyri) - Therapeutics under Investigation by Universities/Institutes
Porphyria (Erythropoietic Protoporphyri) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Porphyria (Erythropoietic Protoporphyri) - Products under Development by Companies
Porphyria (Erythropoietic Protoporphyri) - Products under Investigation by Universities/Institutes
Porphyria (Erythropoietic Protoporphyri) - Companies Involved in Therapeutics Development
Alnylam Pharmaceuticals, Inc.
Clinuvel Pharmaceuticals Limited
Digna Biotech, S.L.
UniQure N.V.
Porphyria (Erythropoietic Protoporphyri) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
afamelanotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-AS1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMT-021 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DB-027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enzyme Replacement Therapy for Acute Intermittent Porphyria - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Porphyria (Erythropoietic Protoporphyri) - Recent Pipeline Updates
Porphyria (Erythropoietic Protoporphyri) - Discontinued Products
Porphyria (Erythropoietic Protoporphyri) - Product Development Milestones
Featured News & Press Releases
Mar 24, 2016: NICE’s technical team invited stakeholders with an interest in the treatment of erythropoietic protoporphyria
Feb 16, 2016: Clinuvel brief on European commercialisation
Feb 12, 2016: SCENESSE receives US FDA orphan designation for cutaneous porphyrias
Sep 15, 2015: Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 for the Treatment of Acute Hepatic Porphyrias
Aug 27, 2015: FDA grants Clinuvel a Type C Meeting
Jul 02, 2015: New England Journal of Medicine publishes pivotal Phase III SCENESSE studies
Jul 01, 2015: Treatment Reduces Symptoms in Syndrome that Causes Extreme Light Sensitivity
Jul 01, 2015: Treatment Reduces Symptoms in Syndrome that Causes Extreme Light Sensitivity
Jun 05, 2015: SCENESSE Commercialisation Update
May 26, 2015: Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Porphyria (Erythropoietic Protoporphyri), H1 2016
Number of Products under Development for Porphyria (Erythropoietic Protoporphyri) - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Porphyria (Erythropoietic Protoporphyri) - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
Porphyria (Erythropoietic Protoporphyri) - Pipeline by Clinuvel Pharmaceuticals Limited, H1 2016
Porphyria (Erythropoietic Protoporphyri) - Pipeline by Digna Biotech, S.L., H1 2016
Porphyria (Erythropoietic Protoporphyri) - Pipeline by UniQure N.V., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Porphyria (Erythropoietic Protoporphyri) Therapeutics - Recent Pipeline Updates, H1 2016
Porphyria (Erythropoietic Protoporphyri) - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Porphyria (Erythropoietic Protoporphyri), H1 2016
Number of Products under Development for Porphyria (Erythropoietic Protoporphyri) - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report